Answers are grounded in this paper and cite their sources.
Chronic kidney disease (Ckd) is an emerging non-communicable disease with a growing disease burden.Currently, available medications do not control its progression to end-stage renal disease.Alternate therapies such as flavonoids are researched because of their multiple activities.Diosmin, currently marketed for chronic venous insufficiency, is investigated in this study because of its reported pharmacological activities.Adenine-induced chronic kidney disease is more relevant to human Ckd than other Ckd models in rats.The molecule was investigated in vivo for its nephroprotective activity is proved to be effective through its antioxidant effects.At 200 mg/kg dose, diosmin has prevented the progression of Ckd by normalizing SOD, GSH, and MDA levels in rats.Also, histopathological studies reveal kidney protection in diosmin-treated groups.Thus, diosmin in the present study has proved to be protective in adenine-induced chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Deepthi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: